Finance

Beta
Lists
VOR:NASDAQ
Vor Biopharma Inc
$16.10
+7.84%
(+1.17) 1D
$15.45
-4.04% (-0.65)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VOR...
Open
$15.04
High
$16.28
Low
$14.97
Mkt. cap
872.39M
Avg. vol.
912.38K
Volume
8.13M
52-wk high
$65.80
52-wk low
$6.50
EPS
-$293.09
Beta
1.71
Shares outstanding
54.19M
No. of employees
76
Open
$15.04
High
$16.28
Low
$14.97
Mkt. cap
872.39M
Avg. vol.
912.38K
Volume
8.13M
52-wk high
$65.80
52-wk low
$6.50
EPS
-$293.09
Beta
1.71
Shares outstanding
54.19M
No. of employees
76
News stories
From sources across the web
About Vor Biopharma Inc
CEO-
Employees76
Founded2015
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitevorbio.com
Analyst ratings
Based on 6 analysts giving stock ratings to VOR in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for VOR in the last 3 months.
Highest
Current $16.10
$50.00 (+210.56%)
Average
$33.80 (+109.94%)
Lowest
$18.00 (+11.80%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$31.00
+92.5%
05/18/2026
Martin Fan
Wedbush
Hold
Maintained
$18.00
+11.8%
05/14/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$30.00
+86.3%
05/13/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/13/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$40.00
+148.4%
04/08/2026
Farzin Haque
Jefferies
Buy
Initiated
$50.00
+210.6%
03/29/2026
Geoff Meacham
Citi
Buy
Maintained
$50.00
+210.6%
01/30/2026
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$5.11 / -$0.78
-553.04%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
241.15M
14.72M
19.19M
17.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.40M
14.42M
16.77M
17.56M
Operating expense
243.55M
29.14M
35.96M
35.16M
Total operating expenses
243.55M
29.14M
35.96M
35.16M
Operating income
-243.55M
-29.14M
-35.96M
-35.16M
Other non operating income
-1.30B
-786.31M
1.75B
-188.36M
EBT including unusual items
-1.57B
-812.68M
1.72B
-219.58M
EBT excluding unusual items
-1.54B
-813.71M
1.72B
-219.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-1.57B
-812.68M
1.72B
-219.58M
Net profit margin
-
-
-
-
Earnings per share
-251.20
-121.63
307.53
-0.73
Interest and investment income
537.00K
1.73M
2.80M
3.94M
Interest expense
-
-
-
-
Net interest expenses
537.00K
1.73M
2.80M
3.94M
Depreciation and amortization charges
-
-
-
-
EBITDA
-241.51M
-29.13M
-35.94M
-35.13M
Gain or loss from assets sale
3.30M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of VOR
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer